Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: January 28, 2000
Last updated: January 15, 2013
Last verified: January 2013

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy tissues.

PURPOSE: This phase II trial is studying isolated limb infusion of chemotherapy to see how well it works in treating patients with melanoma or soft tissue sarcoma of the arm or leg that cannot be removed by surgery.

Condition Intervention Phase
Melanoma (Skin)
Biological: dactinomycin
Drug: isolated limb perfusion
Drug: melphalan
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • Efficacy
  • Morbidity
  • Expression of melanoma-associated antigens

Estimated Enrollment: 35
Study Start Date: August 1999
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the efficacy of isolated limb infusion (ILI) with melphalan and dactinomycin in patients with primary or recurrent, unresectable regional melanoma or soft tissue sarcoma of the extremity.
  • Determine the morbidity of patients treated with this regimen.
  • Determine the expression of melanoma-associated antigens as well as cellular and humoral immune responses to these antigens in patients with regional disease.

OUTLINE: Patients undergo fluoroscopic placement of angiographic arterial and venous catheters into the appropriate extremity. After the limb is warmed, melphalan and dactinomycin are rapidly infused into the isolated limb via the arterial catheter. Melphalan and dactinomycin are then recirculated for 20 minutes. Patients with little or no response at 8 weeks may receive up to 2 additional treatments at the discretion of the treating physician.

Patients are followed at 1-2 weeks, 3-4 weeks, 6-8 weeks, and then every 3-6 months thereafter as deemed necessary by the treating physician.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 3 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven primary or recurrent, regional melanoma or soft tissue sarcoma that is not amenable to surgical resection

    • Majority (greater than 95%) of disease must be distal to the apex of the femoral triangle in the lower limb and the deltoid insertion in the upper limb
  • Bidimensionally measurable disease in the extremity
  • Patients with disease beyond the limb are eligible if their extremity disease requires palliative treatment in the judgment of their physician



  • Over 18

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • At least 6 months


  • WBC at least 3,000/mm^3


  • Not specified


  • Creatinine less than 2.0 mg/dL


  • Must have palpable femoral/axillary, dorsalis pedis/popliteal, or radial pulses in the extremity to be treated
  • No signs or symptoms of vascular insufficiency (no history of claudication or other ischemic peripheral vascular disease)


  • Not pregnant or nursing
  • Negative pregnancy test
  • No other concurrent serious illness
  • No severe diabetes

    • No prior extremity complications due to diabetes


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified


  • At least 4 weeks since prior antitumor therapy and recovered
  • At least 2 weeks since prior antibiotics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004250

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Mary S. Brady, MD Memorial Sloan Kettering Cancer Center
  More Information

Publications: Identifier: NCT00004250     History of Changes
Other Study ID Numbers: 99-047
Study First Received: January 28, 2000
Last Updated: January 15, 2013

Keywords provided by Memorial Sloan Kettering Cancer Center:
stage III adult soft tissue sarcoma
recurrent adult soft tissue sarcoma
stage III melanoma
stage IV melanoma
recurrent melanoma
stage IV adult soft tissue sarcoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms, Connective and Soft Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Protein Synthesis Inhibitors
Enzyme Inhibitors
Nucleic Acid Synthesis Inhibitors processed this record on April 26, 2017